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Drug treatment is an important option for the treatment 
of peripheral vestibular diseases. Aim: To identify the drug 
component associated with optimal integrated balance thera-
py (IBT) for Ménière’s disease or other peripheral vestibular 
disorders. Materials and Methods: Analysis of a series of 
patients with Ménière’s disease patients or patients with other 
peripheral vestibular disorders that received IBT involving 
either no medication or betahistine, cinnarizine, clonazepam, 
flunarizine or Ginkgo biloba during 120 days. Results: In 
Ménière’s disease, significant differences were observed for 
all drug therapies (60 days) versus no medication; betahistine 
was significantly more effective than all other drugs at 60 and 
120 days. For non-Ménière’s disorders, significant differences 
were observed among betahistine, cinnarizine, clonazepam 
and flunarizine and no medication after 60 days; all drug 
therapies were significantly more effective than no medication 
after 120 days; betahistine, cinnarizine or clonazepam were 
equally effective and betahistine was more effective than 
flunarizine and EGb 761. All treatment options were well 
tolerated. Conclusions: Drug therapies were more effective 
than no medication in the IBT for patients with Ménière’s 
disease or other peripheral vestibular disorders. Betahistine 
was the most effective medication for patients with Ménière’s 
disease and was as effective as cinnarizine and clonazepam 
for other peripheral vestibular disorders.
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INTRODUCTION
According to randomized, double blind, placebo-
controlled studies and literature reviews, monotherapeutic 
strategies may not be enough to bring about complete 
vertigo resolution.1 A precise diagnosis is essential in order 
to control vertigo1-2 The combination of clinical history and 
otoneurologic findings leads us towards lesion detection 
and proper diagnosis. Besides its clinical value, otoneuro-
logic assessments may contribute to treatment definition 
and prognosis, and it also supports patient follow up.3
Although there are many options to ameliorate or 
totally resolve vestibular vertigo and associated symptoms, 
therapy must be designed based on specific patient disor-
der, considering the resolution of underlying diseases, ver-
tigo control, neurovegetative and psychoaffective related 
symptoms, the improvement in vestibular compensation 
and the prevention of aggravating factors.1,4 A quick onset 
of therapeutic action is paramount in order to restore the 
patient’s well being; treatment has to be well tolerated, 
and bear a low incidence of adverse effects.1
Therapeutic results in patients with vestibular ver-
tigo improve significantly with the concurrent use of etio-
logical control, pharmacotherapy, customized vestibular 
rehabilitation exercises, diet control and life style changes. 
The use of a combined therapeutic modality may lead to 
improvements or faster and more long lasting recoveries 
when compared to monotherapy alone.1
Both Nocebo and placebo effects are also present 
in clinical practice.4-5 In a placebo-controlled study of an 
active drug, vertigo improvement or resolution was seen 
in only 14.7% of the non-treated patients, and in 40.1% of 
the control patients who were taking some placebo drug; 
when  only the assumed cause was treated, 36.9% of the 
patients improved.6 Etiologic treatment is Paramount, but 
it does not offer the patient a significant improvement or 
vertigo symptoms resolution when used alone.6 In order 
to promote vestibular compensation, rehabilitation exer-
cises should include habituation of abnormal responses, 
postural control exercises, visual-vestibular interaction 
and conditioning activities.1,7-8 Vestibular rehabilitation 
exercises were efficient in 51.1% of the patients when 
used alone.6 Malnutrition and bad feeding habits are 
common worsening factors, and they may even represent 
likely vertigo etiologic factors.1,8-9 Diet and feeding habit 
changes improve vertigo in 42.2% of the patients with 
vestibulopathies.6
Many safe and efficient anti-vertigo drugs are cur-
rently available. Clinical experience has shown that 16 mg 
of betahistine TID; 12.5 mg of cinnarizine TID; 0.5 mg of 
clonazepam, BID; 5 mg of flunarizine, BID; or 80 mg of 
ginkgo biloba extract (EGb 761), TID may be useful in 
vertigo control.3,6,8
There is evidence of a significant inverse correlation 
between the anti-vertigo action of clonazepam, cinnarizine 
or flunarizine and their daily doses.10-11 Betahistine pro-
motes and facilitates central vestibular compensation.12-14 
EGb 761 accelerates postural and locomotor balance and 
oculomotor function recovery.15
Betahistine is an H
3
 heteroreceptor antagonist 
and an H1 receptor agonist16-17 able to improve inner ear 
microcirculation.17 It is used in the treatment of numerous 
vestibulopathies.8,17-19 There may be side effects such as he-
adaches and epigastric discomfort; gastrointestinal ulcers, 
asthma and pheochromocytoma are counter-indications 
to the use of this drug.8 H1 receptor blockers and fluna-
rizine, cinnarizine and calcium antagonists inhibit vessel 
constriction and act as vestibular sedative drugs, used in 
the treatment of both central and peripheral vertigo.8,20-24 
Fatigue, sleepiness, epigastric discomfort, weight gain, 
depression and extrapyramidal symptoms are the main 
adverse effects seen with the use of both drugs. They are 
both counterindicated in patients with extrapyramidal 
disorders.8 Flunarizine is also employed in the treatment 
of migraine.25 Clonazepam is a benzodiazepine drug that 
increases the inhibitor effect of gama-amino-butyric acid 
in the vestibular nuclei, and is useful in vertigo therapy 
and in controlling anxiety and panic spells in vertiginous 
patients. Patients may experience sleepiness, fatigue and 
drug addiction. Myasthenia gravis and narrow angle acu-
te glaucoma are its counterindication.8-11 EGb 761 bears 
hemodynamic, hemorheologic, metabolic and neural 
effects.8,26 It is used to treat both central and peripheral 
vertigo.8,27-28 Headache, hypotension and gastrointestinal 
disorders are its main side effects.8
Vertigo improvement was seen with drug therapy 
alone in 75.1% of the patients with peripheral vestibulo-
pathies and in 39.8% of the patients with central vestibular 
disorders.29
Results attained from a single treatment modality 
were usually worse than those attained with some com-
bined therapy. Nonetheless, a combination of therapy 
modalities brought about vertigo improvement in 96.0% 
of the cases.1,6,8
The goal of the present investigation is to assess the 
vertigo integrated therapy (VIT) efficacy and safety, based 
on concurrent approaches that include etiologic treatment, 
customized rehabilitation exercises, diet control and life 
style changes, with or without medication
PATIENTS AND METHODS
This study was approved by the Ethics Committee 
of our institution, under protocol # 0973/04.
We consulted the charts of 1,100 outpatients with 
established Ménière’s disease  or other peripheral vesti-
bulopathies treated by VIT, including etiologic treatment, 
personalized rehabilitation exercises, diet control and life 
style changes, with or without antivertigo substance use, 
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and check if there was vertigo improvement. Established 
Ménière’s disease was defined based on the criteria from 
the American Academy of Otorhinolaryngology-Head and 
Neck Surgery: 1) Two or more spontaneous vertigo episo-
des lasting 20 minutes or more; 2) hearing loss documented 
by audiometry in at least one occasion; 3) tinnitus or ear 
fullness in the treated ear; 4) ruling out other causes.30 
Ménière patients who suffered at least three vertigo episo-
des in the two previous months were considered eligible. 
Patients with peripheral vestibulopathies that were not 
Ménière’s disease were included if they suffered recurrent 
vertigo, instability between crises or continuous diziness in 
the two prior months.8 All the patients received treatment 
for 120 consecutive days.
The patients underwent a careful examination, in-
cluding clinical history; ear, nose and throat exam; audio-
metry and vestibular assessment, including electronystag-
mography before and after VIT. Auditory assessment was 
based on threshold tonal audiometry, speech recognition 
threshold and immitance test. We included tests of brain 
stem auditory response and/or electrocochleography when 
necessary. Balance assessment included caloric, gait and 
posture tests, positional nystagmus, spontaneous nystag-
mus, semi-spontaneous nystagmus, saccadic movements, 
pendular tracking, optokinetic nystagmus and self-rotation 
of the head.
After detecting the assumed etiology for the ves-
tibular disorder, we started a specific treatment for the 
underlying disease. A personalized rehabilitation program, 
including habituation, sensorial substitution or adaptative 
mechanisms were applied according to the specific vesti-
bular disorder suffered by each patient. 
The patients were instructed to eat lavishly during 
breakfast, have a light lunch and an even lighter dinner, 
avoiding intervals greater than 3 hours in between meals, 
as well as avoiding the use of  refined sugar, coffee, alcohol 
and tobacco. They were encouraged to practice physical 
exercises according to their own physical condition.
The patients were randomized to receive no medica-
tion or oral drug therapy made up of 16 mg of betahistine 
TID; 12.5 mg of cinnarizine TID; 80 mg of EGb 761, TID; 
0.5 mg of clonazepam BID; or 0.5 mg of flunarizine, once a 
day before going to sleep. The use of other antivertiginous 
drug was not allowed. 
The patients were examined in three occasions: 
at study admittance; two and four months after therapy 
onset. The variable used to assess treatment efficacy was 
the patient’s overall impression. Efficacy was assessed ac-
cording to the patient’s subjective response after the end 
of each treatment period. Efficacy assessment used the 
following classifications: 1 = no symptoms (full recovery), 
2 = very good improvement, 3 = good improvement, 4 
= mild response and 5 = no response. The patients who 
reported having very good, good and mild improvement 
were included in the category of those who improved 
(with partial improvement). Tolerability was assessed by 
the investigators and the patients themselves at the end 
of each treatment period. 
Statistical analysis
We used statistical analysis in order to detect pos-
sible differences in the efficacy rates between patients 
assigned to the six VIT groups, considering the disease 
presented and treatment response. Treatment groups were 
compared using the chi-squared Pearson’s test at a 5% 
significance level. 
RESULTS
Of the 1,100 patients selected for the study, 603 
(54.8%) were women and 497 (45.2%) were men; ave-
rage age was of approximately 48 years; 283 (25.%) had 
Ménière’s disease and 817 (74.3%) had peripheral vestibular 
disorders. Table 1 depicts patient distribution as to having 
Ménière’s disease or other peripheral vestibular disorders 
according to VIT treatment group. The rate of Ménière 
patients or those with other vestibular disorders was not 
different among the groups (p=0.105). Table 2 shows the 
treatment effects on Ménière’s disease patients.
Table 1. Patient distribution according to Vertigo Integrated Therapy and the vestibular disorder.
VIT Group Ménière’s Disease Other vestibular disorders Total
N % N %
Betahistine 62 32.1 131 67.9 193
Cinnarizine 60 29.7 142 70.3 202
Clonazepam 44 23.5 143 76.5 187
Flunarizina 41 22.9 138 77.1 179
EGb 761 41 23.3 135 76.7 176
No medication 35 21.5 128 78.5 163
Total 283 25.7 817 74.3 1,100
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Table 2. Results from the Vertigo Integrated Therapy in patients with Ménière’s disease.
VIT Group Asymptomatic Improved No change
60 days 120 days 60 days 120 days 60 days 120 days
N % N % N % N % N % N %
Betahistine 6 9.7 31 50.0 45 72.6 24 38.7 11 17.7 7 11.3
Cinnarizine 4 6.7 17 28.3 36 60.0 28 46.7 20 33.3 15 25.0
Clonazepam 3 6.8 11 25.0 24 54.5 20 45.5 17 38.6 13 29.5
Flunarizine 2 4.9 8 19.5 18 43.9 19 46.3 21 51.2 14 34.1
EGb 761 2 4.9 8 19.5 17 41.5 18 43.9 22 53.7 15 36.6
No medication 0 0.0 5 14.3 5 14.3 14 14.0 30 85.7 16 45.7
Table 3. Vertigo Integrated Therapy results in patients with vestibulopathies, excluding Ménière’s disease.
VIT Group Asymptomatic Improved Unaltered
60 days 120 days 60 days 120 days 60 days 120 days
N % N % N % N % N % N %
Betahistine 14 10.7 71 54.2 91 69.5 49 37.4 26 19.8 11 8.4
Cinnarizine 10 7.0 48 33.8 92 64.8 69 48.6 40 28.2 25 17.6
Clonazepam 11 7.7 48 33.6 97 67.8 75 52.4 35 24.5 20 14.0
Flunarizine 8 5.8 49 35.5 80 58.0 70 50.7 50 36.2 19 13.8
EGb 761 6 4.4 40 29.6 74 54.8 70 51.9 55 40.7 25 18.5
No medication 2 1.6 17 13.3 63 49.2 49 38.3 63 49.2 62 48.3
Table 4. Adverse events prevalence in the groups that received the Vertigo Integrated Therapy.
Adverse Event VIT Group
Betahistine Cinnarizine Clonazepam Flunarizine EGb 761 No medication Total
N % N % N % N % N % N % N %
Sleepiness 0 0.0 48 23.8 49 26.2 53 29.6 0 0.0 0 0.0 150 13.3
Depression 4 2.1 15 7.4 17 9.1 24 13.4 5 2.8 28 17.1 93 8.5
Headache 16 8.3 15 7.4 11 5.9 17 9.5 16 9.1 13 8.0 88 8.0
Anxiety 6 3.` 5 2.5 0 0.0 4 2.2 8 4.5 24 14.7 47 4.3
Epigastric dis-
comfort
10 5.2 6 2.9 5 2.7 5 2.8 11 6.3 7 4.3 44 4.0
Urinary retention 3 1.6 12 5.9 4 2.1 17 9.5 2 1.1 3 1.8 41 3.7
Weight gain 2 1.0 15 7.4 2 1.1 18 10.1 1 0.6 2 1.2 39 3.5
Dry mouth 0 0.0 19 9.4 0 0.0 17 9.5 0 0.0 0 0.0 36 3.3
Fatigue 2 1.0 9 5.5 4 2.1 11 6.1 3 1.7 6 3.7 3.5 3.2
Insomnia 4 2.1 4 2.5 2 1.1 3 1.7 3 1.7 11 6.7 27 2.5
Libido reduction 1 0.5 5 2.5 5 2.7 6 3.4 2 1.1 2 1.2 21 1.9
Palpitation 3 1.6 4 2.0 3 1.6 5 2.8 3 1.7 3 1.8 13 1.2
Nausea 2 1.0 2 1.0 1 0.5 2 1.1 3 1.7 2 1.2 12 1.1
Dyspepsia 2 1.0 2 1.0 1 0.5 1 0.6 3 1.7 3 1.8 12 1.1
Lipothymia 1 1.0 2 1.0 0 0.0 1 0.6 1 0.6 3 1.8 8 0.7
Arterial hypotension 1 1.0 2 1.0 0 0.0 2 1.1 1 0.6 1 0.6 7 0.6
Blurred vision 0 0.0 0 0.0 1 0.5 3 1.7 0 0.0 1 0.6 5 0.4
Skin rash 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.6 1 0.1
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As to the percentage of asymptomatic patients with 
Ménière’s disease and those with it that improved after 
60 days of treatment, statistically significant differences 
were seen between betahistine (p<0.0001), cinnarizine 
(p<0.0001), clonazepam (p<0.0001), flunarizine (p=0.0014) 
or EGb 761 (p=0.0027) and VIT without medication. The 
percentage of patients who presented full and partial 
resolution was greater in all the groups that received VIT 
with medication when compared to those who did not. 
The group treated with betahistine presented a significan-
tly higher full and partial resolution when compared to 
cinnarizine (p=0.048), clonazepam (p=0.016), flunarizine 
(p<0.0005) or EGb 761 (p=0.0001). The group treated 
with cinnarizine had a higher partial and full resolution 
rate when compared to the group receiving EGb 761 
(p=0.042).
As to the percentage of patients with Ménière’s dise-
ase who were asymptomatic or improved after 120 days of 
treatment, statistically significant differences were observed 
favoring betahistine (p<0.001) and cinnarizine (p=0.038) 
when compared to no medication. Patients treated with 
betahistine presented a significantly higher percentage of 
full and partial resolution when compared to those under 
cinnarizine (p=0.049), clonazepam (p=0.018), flunarizine 
(p=0.005) or EGb 761 (p=0.002).
Table 3 depicts treatment effects in patients with 
vestibular disorders, excluding Ménière’s disease. 
As to the percentage of patients with periphe-
ral vestibular disorders, excluding Mèniére, who were 
asymptomatic and improved after 60 days of treatment, 
statistically significant differences were observed between 
betahistine (p<0.0001), cinnarizine (p<0.0005), clonaze-
pam (p<0.0001) or flunarizine (p=0.0322) and no medi-
cation. The groups treated with betahistine, cinnarizine, 
clonazepam or flunarizine presented higher percentages 
of complete and partial improvements when compared 
to the groups that did not receive medication treatment. 
Betahistine was associated to a higher rate of partial and 
complete symptoms relief when compared to flunarizine 
(p=0.0029) or EGb 761 (p=0.002). Cinnarizine was asso-
ciated with a higher percentage of complete and partial 
symptoms relief when compared to EGb 761 (p=0.,0276). 
Clonazepam was associated to a higher rate of complete 
and partial symptoms relief when compared to flunarizine 
(p=0.0320) or EGb 761 (p=0.0038).
As to the percentage of patients with other peri-
pheral vestibular disorders, Ménière excluded, who were 
asymptomatic and improved after 120 days of treatment, 
statistically significant differences were observed between 
betahistine (p<0.001), cinnarizine (p<0.001), clonazepam 
(p<0.001), flunarizine (p=0.001) or EGb 761 (p=0.001) 
and no medication. Betahistine, cinnarizine, clonazepam, 
flunarizine and EGb 761 were associated to a higher rate 
of complete and partial improvements when compared to 
no medication. Betahistine was associated to a higher rate 
of complete and partial improvement when compared to 
flunarizine (p=0.025) or EGb 761 (p=0.001).
All treatment modalities were well tolerated, with 
a low incidence of adverse effects. Severe adverse effects 
were not reported. Medication termination was not re-
quired in any of the cases. Table 4 depicts adverse effect 
events in the groups that received VIT. When compared 
with ciniarizine, clonazepam and flunarizine, betahistine 
presented a substantially lower incidence of the most 
seen adverse effects such as sleepiness and depression, 
and a comparable or lower incidence of most of the other 
adverse effects when compared to the group that did not 
receive any medication. 
DISCUSSION
The present study provides enough evidence of 
the antivertiginous efficacy and excellent tolerability of a 
VIT that included etiologic treatment, personalized reha-
bilitation exercises, diet control, life style changes and 
drug therapy with betahistine, cinnarizine, clonazepam, 
flunarizine or EGb 761.
It has been established that betahistine 8,17-19, 
cinnarizine23-24, clonazepam8,11, flunarizine23-24, or EGb 
7618,27-28 ameliorate vestibular vertigo. In the treatment of 
Ménière’s diseases, betahistine proved eficatious8,31 and 
is more efficient than cinnarizine in reducing instability 
after vestibular neurectomy and in increasing vestibular 
compensation efficiency.32 Flunarizine also has a positive 
therapeutic effect.33
In our study, all five substances studied were more 
efficient when compared to no medication at all after two 
months of VIT in patients with Ménière’s disease. After 
four months of therapy, only betahistine or cinnarizine 
were more efficient than no medication. Betahistine was 
more efficient than cinnarizine, clonazepam, flunarizine or 
EGb 761 after two and four months of therapy. Betahistine, 
cinnarizine or clonazepam have all a better antivertiginous 
effect significantly earlier than that of flunarizine, EGb 761 
or no medication. 
In treating peripheral vestibular vertigo, betahistine8,18-
19, cinnarizine6,8,23,29, clonazepam6,8,11,29, flunarizine6,8,11,29, and 
EGb 7616,8,11,29 proved to be efficacious; on the other hand, 
betahistine proved to be more efficient than flunarizine34 
and similar to EGb 761.28
After two and four months of VIT in patients with 
peripheral vestibular disorders, excluding Ménière’s dise-
ase, betahistine, cinnarizine, clonazepam or flunarizine 
were more efficient than no medication at all. All the drugs 
studied reached their best antivertiginous effects after four 
months of treatment.
It is possible that some of the therapeutic failures 
have happened because of the very difficulty in detec-
ting or controlling an underlying disease, the patient’s 
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difficulty in complying with treatment protocol, perform 
the rehabilitation exercises, follow diet recommendations 
and change life style habits. On the other hand, etiologic 
control of aggravating factors and the responses from the 
balance rehabilitation program may have varied according 
to the patient and the vestibular disorder, and may have 
had a different impact on the groups that underwent drug 
therapy.
Patient compliance is important in order to reach 
the therapeutic effect desired, and the incidence of adverse 
effects may impact this compliance. Therefore, it is worth 
mentioning that, in the present study, betahistine was 
associated to a substantially lower incidence of adverse 
effects such as sleepiness and depression when compared 
to cinnarizine, clonazepam and flunarizine, and a com-
parable or lower incidence of most of the other adverse 
events when compared to the group that did not receive 
any medication. 
The highest rates of improvement seen with a VIT 
that included medication usage were possible due to the 
summation of favorable effects reached by combined 
strategies. Favorable results associated to a good tolera-
bility suggest that VIT is a good option to use in order to 
control vertigo in patients with Ménière’s disease or other 
peripheral vestibular disorders. 
CONCLUSION
In a combination of therapeutic modalities used 
to treat Ménière’s disease or other peripheral vestibular 
disorders, betahistine, cinnarizine, clonazepam, flunarizine 
or EGb 761 are more efficient than not using medication at 
all; betahistine is the most efficient medication to be used 
in patients with Ménière’s disease; betahistine, cinnarizine 
or clonazepam are equally efficient, and betahistine is 
more efficient than flunarizine or EGb 761 in patients with 
peripheral vestibular disorders, not considering Ménière’s 
disease. 
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